SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+3.25%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.56B
AUM Growth
+$1.56B
(-5.2%)
Cap. Flow
-$70.3M
Cap. Flow
% of AUM
-4.51%
Top 10 Holdings %
Top 10 Hldgs %
66.12%
Holding
83
New
13
Increased
14
Reduced
20
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$29.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$18.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$17.3M |
| 4 |
Zoetis
ZTS
|
$14.8M |
| 5 |
Zymeworks
ZYME
|
$11.9M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$33.4M |
| 2 |
Biogen
BIIB
|
$21.9M |
| 3 |
Neurocrine Biosciences
NBIX
|
$19.8M |
| 4 |
Insulet
PODD
|
$19.2M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$17.8M |
Sector Composition
| 1 | Healthcare | 98.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Fate Therapeutics
FATE
$115M
| – | – |
-46,386
| Closed | -$4.03M |
|
77
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| – | – |
-434,555
| Closed | -$6.01M |
|
78
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
0
| – | – |
|
79
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-158,609
| Closed | -$2.51M |
|
80
ARK Genomic Revolution ETF
ARKG
$1.05B
| – | – |
0
| – | – |
|
81
Amgen
AMGN
$153B
| – | – |
-40,500
| Closed | -$9.87M |
|
82
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-219,033
| Closed | -$12.1M |
|